title: Atenolol for the prevention of arrhythmias following coronary artery bypass grafting.
abstract: Seventy patients undergoing aortocoronary bypass grafting were randomized, double-blind, to receive either atenolol or placebo. There were 35 patients in each group. Patients received either atenolol 5 mg intravenously or matching placebo within 3 h of the completion of surgery. A second intravenous dose was administered 24 h following the first and then atenolol 50 mg orally or matching placebo was given for six days. Continuous Holter monitor recordings were obtained for the 24 h immediately preoperatively and continuously for eight days postoperatively. No patient received any antiarrhythmic drug preoperatively. Patients who required pharmacological intervention for the management of postoperative arrhythmias were withdrawn as treatment failures. Holter monitor analysis continued for 24 h following withdrawal of a treatment failure. All patients were analyzed according to the intention-to-treat principle. Both groups were comparable with respect to age, sex, severity of coronary artery disease, left ventricular ejection fraction, preoperative use of beta-blockers, bypass time, aortic cross-clamp time, number of grafts per patient and frequency of preoperative arrhythmias. Arrhythmia analysis was done manually. Supraventricular arrhythmias (atrial tachycardia, atrial fibrillation and atrial flutter) were classified as either mild (less than 0.5 mins, less than 140 beats/min), moderate (0.5 to 30 mins, 140 to 180 beats/min), or severe (longer than 30 mins, more than 180 beats/min). Ventricular arrhythmia analysis was performed with respect to isolated PVCs, couplets, triplets and episodes of nonsustained ventricular tachycardia.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Cardiology, Plains Health Centre, Regina, Saskatchewan.
authors.forename: M F
authors.initials: MF
authors.lastname: Matangi
authors.forename: J
authors.initials: J
authors.lastname: Strickland
authors.forename: G J
authors.initials: GJ
authors.lastname: Garbe
authors.forename: N
authors.initials: N
authors.lastname: Habib
authors.forename: A K
authors.initials: AK
authors.lastname: Basu
authors.forename: J J
authors.initials: JJ
authors.lastname: Burgess
authors.forename: A
authors.initials: A
authors.lastname: Maitland
authors.forename: E F
authors.initials: EF
authors.lastname: Busse
mesh_terms: D000368:Aged; D001262:Atenolol / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D013617:Tachycardia, Supraventricular / Q000209:etiology / Q000517:prevention & control*
chemical_list: D001262:Atenolol